



(12) **CORRECTED EUROPEAN PATENT APPLICATION**
published in accordance with Art. 153(4) EPC

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 54

(48) Corrigendum issued on:
02.10.2024 Bulletin 2024/40

(43) Date of publication:
22.05.2024 Bulletin 2024/21

(21) Application number: **22841217.7**

(22) Date of filing: **04.07.2022**

(51) International Patent Classification (IPC):
C07K 16/18 ^(2006.01) **G01N 33/68** ^(2006.01)
G01N 33/577 ^(2006.01) **G01N 33/574** ^(2006.01)

(52) Cooperative Patent Classification (CPC):
G01N 33/57419; C07K 16/18; C07K 16/26;
G01N 33/57446; G01N 33/6893; C07K 2317/92;
G01N 2800/062; G01N 2800/065; G01N 2800/067

(86) International application number:
PCT/CN2022/103719

(87) International publication number:
WO 2023/284579 (19.01.2023 Gazette 2023/03)

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: **14.07.2021 CN 202110798131**

(71) Applicant: **Senboll Biotechnology Co., Ltd.**
Shenzhen, Guangdong 518118 (CN)

(72) Inventors:
• **GUO, Jian**
Shenzhen, Guangdong 518118 (CN)

- **WANG, Xinying**
Guangzhou, Guangdong 510000 (CN)
- **ZHOU, Yaxian**
Shenzhen, Guangdong 518118 (CN)
- **WAN, Desen**
Guangzhou, Guangdong 510060 (CN)
- **FANG, Yujing**
Guangzhou, Guangdong 510060 (CN)
- **OU, Qingjian**
Guangzhou, Guangdong 510060 (CN)
- **FAN, Tingting**
Guangzhou, Guangdong 510000 (CN)

(74) Representative: **ATIP**
Armstrong Teasdale Limited
38-43 Lincoln's Inn Fields
London WC2A 3PE (GB)

(54) **ANTIBODY COMBINATION AGAINST REGENERATING ISLET-DERIVED PROTEIN 1 ALPHA AND DETECTION KIT COMPRISING SAME**

(57) The present invention provides an antibody combination that can be used to detect regenerating islet-derived protein 1 α (REG1A), each antibody in the antibody combination can specifically bind to REG1A with high affinity so as to form a double-antibody sandwich form, thereby enabling qualitative and quantitative detection of human REG1A. The antibody combination or an ELISA detection kit comprising the antibody combination can be used for auxiliary diagnosis or disease risk prediction of REG1A-related diseases.




Fig. 2